Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
From redefining what “no-option” truly means, to understanding the role of small artery disease and medial arterial calcification in decision-making, this discussion highlights both clinical data and real-world experience with LimFlow.
From redefining what “no-option” truly means, to understanding the role of small artery disease and medial arterial calcification in decision-making, this discussion highlights both clinical data and real-world experience with LimFlow.
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone
Late breaking findings...
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone
Late breaking findings...
Randomized IDE study met all primary and secondary safety and efficacy endpoints and demonstrated superior debris capture and significantly higher technical success versus the leading embolic protection control device in TAVR
SANTA CRUZ,...
Randomized IDE study met all primary and secondary safety and efficacy endpoints and demonstrated superior debris capture and significantly higher technical success versus the leading embolic protection control device in TAVR
SANTA CRUZ,...
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
Updated guidance incorporates new research to address non-operative management of BTAI, timing of repair and the management of patients with concomitant traumatic injuries.
Updated guidance incorporates new research to address non-operative management of BTAI, timing of repair and the management of patients with concomitant traumatic injuries.
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
